This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Franovic, A. Articles by Lee, S. Search for Related Content PubMed PubMed Citation Articles by Franovic, A. Articles by Lee, S.

Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17

¹ Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada and ² McGill Cancer Center and Department of Biochemistry, McGill University, Montreal, Quebec, Canada

Requests for reprints: Stephen Lee, Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, Canada K1H 8M5. Phone: 613-562-5800, ext. 8385; Fax: 613-562-5636; E-mail: slee{at}uottawa.ca.

Malignancy is a manifestation of acquired defects in regulatory circuits that direct normal cell proliferation and homeostasis. Most of these circuits operate through cell autonomous pathways, whereas others potentially involve the neighboring microenvironment. We report that the metalloprotease ADAM17 plays a pivotal role in several acquired tumor cell capabilities by mediating the availability of soluble transforming growth factor-, an epidermal growth factor receptor (EGFR) ligand, and thus the establishment of a key autocrine signaling pathway. Silencing of ADAM17 in human renal carcinoma cell lines corrects critical features associated with cancer cells, including growth autonomy, tumor inflammation, and tissue invasion. Highly malignant renal carcinoma cancer cells fail to form in vivo tumors in the absence of ADAM17, confirming the essential function of this molecule in tumorigenesis. These data show that ligand shedding is a crucial step in endogenous EGFR activation and endorse prospective therapeutic strategies targeting ADAM17 in human cancer. (Cancer Res 2006; 66(16): 8083-90)

This article has been cited by other articles:

				L. Ge, D. Baskic, P. Basse, L. Vujanovic, S. Unlu, T. Yoneyama, A. Vujanovic, J. Han, D. Bankovic, M. J. Szczepanski, et al. Sheddase Activity of Tumor Necrosis Factor-{alpha} Converting Enzyme Is Increased and Prognostically Valuable in Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 2913 - 2922. [Abstract] [Full Text] [PDF]

				W. B. Melenhorst, L. Visser, A. Timmer, M. C. van den Heuvel, C. A. Stegeman, and H. van Goor ADAM17 upregulation in human renal disease: a role in modulating TGF-{alpha} availability? Am J Physiol Renal Physiol, September 1, 2009; 297(3): F781 - F790. [Abstract] [Full Text] [PDF]

				M. J. Duffy, E. McKiernan, N. O'Donovan, and P. M. McGowan Role of ADAMs in Cancer Formation and Progression Clin. Cancer Res., February 15, 2009; 15(4): 1140 - 1144. [Abstract] [Full Text] [PDF]

				M. Khacho, K. Mekhail, K. Pilon-Larose, J. Payette, and S. Lee Cancer-Causing Mutations in a Novel Transcription-Dependent Nuclear Export Motif of VHL Abrogate Oxygen-Dependent Degradation of Hypoxia-Inducible Factor Mol. Cell. Biol., January 1, 2008; 28(1): 302 - 314. [Abstract] [Full Text] [PDF]

				A. Franovic, L. Gunaratnam, K. Smith, I. Robert, D. Patten, and S. Lee Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer PNAS, August 7, 2007; 104(32): 13092 - 13097. [Abstract] [Full Text] [PDF]